Previously it was shown that in BRAF mutant melanoma cells, PLX treatment led to a decrease in the protein levels of N-cadherin and MMP2 among other EMT-related markers; however, when resistance to PLX developed, there was a significant increase in the expression of these proteins [31,32]. The gene discussed is MMP2; the disease is melanoma.